TCL.AU

14.1

-2.49%↓

COL.AU

23.56

-0.55%↓

QAN.AU

11.08

-0.09%↓

CAR.AU

38.33

+0.31%↑

WOR.AU

13.96

-1.97%↓

TCL.AU

14.1

-2.49%↓

COL.AU

23.56

-0.55%↓

QAN.AU

11.08

-0.09%↓

CAR.AU

38.33

+0.31%↑

WOR.AU

13.96

-1.97%↓

TCL.AU

14.1

-2.49%↓

COL.AU

23.56

-0.55%↓

QAN.AU

11.08

-0.09%↓

CAR.AU

38.33

+0.31%↑

WOR.AU

13.96

-1.97%↓

TCL.AU

14.1

-2.49%↓

COL.AU

23.56

-0.55%↓

QAN.AU

11.08

-0.09%↓

CAR.AU

38.33

+0.31%↑

WOR.AU

13.96

-1.97%↓

TCL.AU

14.1

-2.49%↓

COL.AU

23.56

-0.55%↓

QAN.AU

11.08

-0.09%↓

CAR.AU

38.33

+0.31%↑

WOR.AU

13.96

-1.97%↓

Search

CSL Ltd

Fechado

SetorSetor Industrial

199.39 -0.55

Visão Geral

Variação de preço das ações

24h

Atual

Mín

199.37

Máximo

201.43

Indicadores-chave

By Trading Economics

Rendimento

2B

Vendas

-5.7B

2.5B

P/E

Médio do Setor

21.688

38.421

EPS

2.04

Rendimento de Dividendos

1.43

Margem de lucro

24.437

Funcionários

29,904

EBITDA

-2.4B

858M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+40.37% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.43%

2.32%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-27B

98B

Abertura anterior

199.94

Fecho anterior

199.39

Sentimento de Notícias

By Acuity

13%

87%

20 / 457 Ranking em Industrials

CSL Ltd Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de set. de 2025, 22:39 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

19 de ago. de 2025, 03:32 UTC

Grandes Movimentos do Mercado

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18 de ago. de 2025, 23:46 UTC

Ganhos

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18 de ago. de 2025, 22:15 UTC

Ganhos

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9 de abr. de 2025, 09:39 UTC

Grandes Movimentos do Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 de fev. de 2025, 21:55 UTC

Ganhos

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

15 de set. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Expects Commercial Launch in 2029

15 de set. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 de set. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 de set. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 de set. de 2025, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

18 de ago. de 2025, 23:46 UTC

Conversa de Mercado
Ganhos

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18 de ago. de 2025, 21:52 UTC

Ganhos

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18 de ago. de 2025, 21:51 UTC

Ganhos

CSL to Cut Up to 15% of Staff>CSL.AU

18 de ago. de 2025, 21:49 UTC

Ganhos

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18 de ago. de 2025, 21:49 UTC

Ganhos

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18 de ago. de 2025, 21:48 UTC

Ganhos

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18 de ago. de 2025, 21:47 UTC

Ganhos

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18 de ago. de 2025, 21:46 UTC

Ganhos

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18 de ago. de 2025, 21:45 UTC

Ganhos

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18 de ago. de 2025, 21:45 UTC

Ganhos

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18 de ago. de 2025, 21:44 UTC

Ganhos

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18 de ago. de 2025, 21:43 UTC

Ganhos

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18 de ago. de 2025, 21:43 UTC

Ganhos

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18 de ago. de 2025, 21:42 UTC

Ganhos

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18 de ago. de 2025, 21:42 UTC

Ganhos

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17 de jun. de 2025, 02:15 UTC

Conversa de Mercado

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 de abr. de 2025, 07:01 UTC

Conversa de Mercado

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 de mar. de 2025, 02:03 UTC

Conversa de Mercado

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 de fev. de 2025, 22:30 UTC

Conversa de Mercado

Flu Vaccines Proving Problematic for CSL -- Market Talk

Comparação entre Pares

Variação de preço

CSL Ltd Previsão

Preço-alvo

By TipRanks

40.37% parte superior

Previsão para 12 meses

Média 283.419 AUD  40.37%

Máximo 330 AUD

Mínimo 227.5 AUD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para CSL Ltd - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

9

Comprar

4

Manter

0

Vender

Sentimento

By Acuity

20 / 457 Ranking em Setor Industrial

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat